GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...

GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.